Jonathan Anderman
Algemeen Adviseur bij COMPASS THERAPEUTICS, INC.
Actieve functies van Jonathan Anderman
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| COMPASS THERAPEUTICS, INC. | Algemeen Adviseur | 01-08-2021 | - |
| Bedrijfssecretaris | 01-08-2021 | - |
Loopbaan van Jonathan Anderman
Eerdere bekende functies van Jonathan Anderman
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 01-01-2020 | 01-08-2021 |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01-08-2015 | 01-08-2018 |
Opleiding van Jonathan Anderman
| Boston University School of Law | Graduate Degree |
| The Pennsylvania State University | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 6 |
Operationeel
| Corporate Officer/Principal | 2 |
| General Counsel | 1 |
| Corporate Secretary | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| COMPASS THERAPEUTICS, INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Beurs
- Insiders
- Jonathan Anderman
- Ervaring
